Translocation t(14;16) and multiple myeloma: Is it really an independent prognostic factor?

Blood

Volumn 117, Issue 6, 2011, Pages 2009-2011

  Avet Loiseau, Hervé ^a   Malard, Florent ^a   Campion, Loic ^b   Magrangeas, Florence ^a   Sebban, Catherine ^c   Lioure, Bruno ^d   Decaux, Olivier ^e   Lamy, Thierry ^e   Legros, Laurence ^f   Fuzibet, Jean Gabriel ^f   Michallet, Mauricette ^g   Corront, Bernadette ^h   Lenain, Pascal ⁱ   Hulin, Cyrille ^j   Mathiot, Claire ^k   Attal, Michel ^l   Facon, Thierry ^m   Harousseau, Jean Luc ^b   Minvielle, Stephane ^a   Moreau, Philippe ⁿ  

^a Team 12   (France)

^b CENTRE RENÉ GAUDUCHEAU   (France)

^c CENTRE LÉON BÉRARD   (France)

^d UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^e RENNES UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY HOSPITAL OF NICE   (France)

^g HOSPICES CIVILS DE LYON   (France)

^h Centre Hospitalier de la Region d'Annecy   (France)

ⁱ CENTRE FRANÇOIS BACLESSE   (France)

^j UNIVERSITY HOSPITAL OF NANCY   (France)

^k INSTITUT CURIE   (France)

^l TOULOUSE UNIVERSITY HOSPITAL   (France)

^m LILLE UNIVERSITY HOSPITAL   (France)

ⁿ NANTES UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 16; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOGENETICS; DISEASE ASSOCIATION; GENE DELETION; GENETIC ASSOCIATION; HUMAN; MULTIPLE MYELOMA; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY;

EID: 79951504474     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-07-295105     Document Type: Article

References (10)

1. Chesi M, Bergsagel PL, Shonukan OO, et al. Frequent dysregulation of the c-maf proto-on-cogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood. 1998;91(12):4457-4463. (Pubitemid 28270291)
2. Hanamura I, Iida S, Akano Y, et al. Ectopic expression of MAFB gene in human myeloma cells carrying the t(14;20)(q32;q11) chromosomal translocations. Jpn J Cancer Res. 2001;92(6): 638-644. (Pubitemid 32633466)
3. Hurt EM, Wiestner A, Rosenwald A, et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell. 2004;5(2):191-199. (Pubitemid 38283804)
4. Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101(7):4569-4575. (Pubitemid 36857829)
5. Nair B, van Rhee F, Shaughnessy JD, et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood. 2010; 115(21):4168-4173.
6. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006; 108(10):3289-3294.
7. Moreau P, Hulin C, Garban F, et al. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. Blood. 2006;107(1):397-403. (Pubitemid 43053569)
8. Facon T, Mary JY, Hulin C, et al. Superiority of melphalan and prednisone chemotherapy plus thalidomide over melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma: results of a randomised IFM trial. Lancet. 2007;370(9594):1209-1218. (Pubitemid 47516593)
9. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood. 2007;109(8):3489-3495. (Pubitemid 46572539)
10. Avet-Loiseau H, Leleu X, Roussel M, et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol. 2010;28(30):4630-4634.